Downloads
Abstract
Background: Chemotherapy is the main treatment that improves symptoms and prolongs the survival
of colorectal cancer patients in the late stage.
Objectives: Evaluate the responses, disease – free survival, overall survival and toxicities of therapies.
Materials and methods: Cross-sectional study in 29 patients with metastatic colorectal cancer.
Results: Good chemotherapy tolerance with major toxicity at 1-2 degrees, can be controlled and didn’t
affect the course of treatment. The rate of disease control after 6 months was 96.6%. The average disease
- free survival was 17.1 ± 9.8 months, the median was 14.5 months. The average overall survival was 21.0
± 12.6 months, median 16.5 months. Conclusion: Bevacizumab helps improve treatment results when
combined with chemotherapy regimens, toxicity on organs at a moderate level and brings relatively high
efficacy in the treatment of metastatic colorectal cancer patients.
Key words: Metastatic colorectal cancer, Bevacizumab plus chemotherapy.
References
GLOBOCAN 2018(IARC) https://gco.iarc.fr/
today/data/factsheets/populations/704-vietnam-fact-sheets.pdf
Đỗ Huyền Nga (2018), “Đánh giá kết quả hóa trị
phác đồ bevacizumab kết hợp FOLFOX4 trong
ung thư đại tràng di căn”, Luận án Tiến sỹ Y học,
Đánh giá kết quả điều trị phác đồ hóa trị...
Bệnh viện Trung ương Huế
Tạp Chí Y Học Lâm Sàng - Số 55/2019 139
Đại học Y Hà Nội, tr 1.
Tol J, Koopman M, and Cats A(2009), “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer”, N Engl J Med. 360, p. 563.
Saltz LB, lenz HJ, and Kindler HL (2007),
“Randomized phase II trial of cetuximab,
bevacizumab, and irinotecan compared with
cetucimab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND -2
study”, J Clin Oncol. 25, p.4557.
Nguyễn Thị Phương Thảo, Trần Thắng (2019),
“Đánh giá kết quả phác đồ Bevacizumab phối
hợp XELOX trong điều trị ung thư đại trực tràng
giai đoạn IV”, Tạp chí Ung thư học Việt Nam, số
-2019, pp. 339 - 343 .
Saltz LB, Clarke S, et al (2008) “ Bevacizumab in
combination with oxaliplatin-based chemotherapy as first- line therapy in metastatic colorectal
cancer: a randomized phase III study”, J Clin
Oncol. 26(12), pp. 2013-2019.
Ocvirk J, Brodowicz T et al (2010), “Cetuximab plus FOLFOX6 or FOLFIRI in metastatic
colorectal cancer: ECOG trial”, World J Gastroenterol, 16(25), pp. 3133-3143.
Lorenzo Antonuzzo, Elisa Giommoni, et al
(2015), “Bevacizumab plus XELOX as first-line
treatment of metastatic colorectal cancer: The
OBELIX study”, World J Gastroenterol, 21(23),
pp. 7281-7288.
Cassidy J, Clarke S, et al (2012), “XELOX vs
FOLFOX4 as first-line therapy for metastatic
colorectal cancer: NO16966 updated results”,
Br J Cancer,105, p.58. .
Nguyễn Thị Sang và cs (2019), “Đánh giá đáp
ứng của Bevacizumab kết hợp XELOX trên bệnh
nhân ung thư đại trực tràng giai đoạn muộn”,
Tạp chí Ung thư học Việt Nam, số 1 -2019, pp.
- 347
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2019 Journal of Clinical Medicine Hue Central Hospital